The estimated Net Worth of Martijn Kleijwegt is at least $184 Тысяча dollars as of 30 April 2018. Mr. Kleijwegt owns over 300,000 units of Eloxx Pharmaceuticals Inc stock worth over $1,772 and over the last 7 years he sold ELOX stock worth over $0. In addition, he makes $182,100 as Independent Director at Eloxx Pharmaceuticals Inc.
Martijn has made over 1 trades of the Eloxx Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 300,000 units of ELOX stock worth $2,925,000 on 30 April 2018.
The largest trade he's ever made was buying 300,000 units of Eloxx Pharmaceuticals Inc stock on 30 April 2018 worth over $2,925,000. On average, Martijn trades about 75,000 units every 0 days since 2018. As of 30 April 2018 he still owns at least 2,953,673 units of Eloxx Pharmaceuticals Inc stock.
You can see the complete history of Mr. Kleijwegt stock trades at the bottom of the page.
Martijn Kleijwegt serves as Independent Director of the Company. Previously served as a member of the Eloxx Limited Board since June 2017. Mr Kleijwegt is a Managing Partner and Co-Owner of Life Sciences Partners (“LSP”) since founding it in 1998. Prior to that, he also was a Partner at Euroventures Ukraine Fund and served as a General Partner at Euroventures Benelux Team. Mr. Kleijwegt has over 30 years of hands-on finance and investment experience and has gained extensive experience in the life sciences sector. He served as a Member of the Supervisory Board and as Non-Executive Director of a number of LSP portfolio companies, including Movetis, Ness, Pronota, ActoGeniX, Prosensa, Eyesense, Crucell, Asoyia, ISTO, Quadrant Plc., Rhein Biotech N.V., and QIAGEN N.V. He currently serves as a Member of the Supervisory Board, or as Non-Executive Director, of the following LSP portfolio companies: OxThera, Orphazyme, Kiadis Pharma and Pharvaris. He received a Master’s degree in Economics from Amsterdam University.
As the Independent Director of Eloxx Pharmaceuticals Inc, the total compensation of Martijn Kleijwegt at Eloxx Pharmaceuticals Inc is $182,100. There are 1 executives at Eloxx Pharmaceuticals Inc getting paid more, with Gregory Williams having the highest compensation of $2,690,850.
Martijn Kleijwegt is 64, he's been the Independent Director of Eloxx Pharmaceuticals Inc since 2017. There are 1 older and 8 younger executives at Eloxx Pharmaceuticals Inc. The oldest executive at Eloxx Pharmaceuticals Inc is Zafrira Avnur, 68, who is the Independent Director.
Martijn's mailing address filed with the SEC is C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Eloxx Pharmaceuticals Inc have traded over $0 worth of Eloxx Pharmaceuticals Inc stock and bought 22,391,804 units worth $47,296,070 . The most active insiders traders include Ran Nussbaum, Tomer Kariv и Steven D Rubin. On average, Eloxx Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $275. The most recent stock trade was executed by Alan Edmund Walts on 1 December 2021, trading 37,695 units of ELOX stock currently worth $23.
eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
Eloxx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: